Literature DB >> 23083226

Why extreme dilutions reach non-zero asymptotes: a nanoparticulate hypothesis based on froth flotation.

Prashant S Chikramane1, Dhrubajyoti Kalita, Akkihebbal K Suresh, Shantaram G Kane, Jayesh R Bellare.   

Abstract

Extreme dilutions, especially homeopathic remedies of 30c, 200c, and higher potencies, are prepared by a process of serial dilution of 1:100 per step. As a result, dilution factors of 10(60), 10(400), or even greater are achieved. Therefore, both the presence of any active ingredient and the therapeutic efficacy of these medicines have been contentious because the existence of even traces of the starting raw materials in them is inconceivable. However, physicochemical studies of these solutions have unequivocally established the presence of the starting raw materials in nanoparticulate form even in these extreme (super-Avogadro, >10(23)) dilutions. In this article, we propose and validate a hypothesis to explain how nanoparticles are retained even at such enormous dilution levels. We show that once the bulk concentration is below a threshold level of a few nanograms/milliliter (ng/mL), at the end of each dilution step, all of the nanoparticles levitate to the surface and are accommodated as a monolayer at the top. This dominant population at the air-liquid interface is preserved and carried to the subsequent step, thereby forming an asymptotic concentration. Thus, all dilutions are only apparent and not real in terms of the concentrations of the starting raw materials.

Mesh:

Substances:

Year:  2012        PMID: 23083226     DOI: 10.1021/la303477s

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  18 in total

1.  Adverse effects and homeopathy: may remedies yet contain noxious or toxic molecules?

Authors:  Salvatore Chirumbolo
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

2.  Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions.

Authors:  Iris R Bell; John A Ives; Wayne B Jonas
Journal:  Dose Response       Date:  2013-11-07       Impact factor: 2.658

3.  Relative Apoptosis-inducing Potential of Homeopa-thic Condurango 6C and 30C in H460 Lung Cancer Cells In vitro: -Apoptosis-induction by homeopathic Condurango in H460 cells.

Authors:  Sourav Sikdar; Santu Kumar Saha; Anisur Rahman Khuda-Bukhsh
Journal:  J Pharmacopuncture       Date:  2014-03

Review 4.  Integrative nanomedicine: treating cancer with nanoscale natural products.

Authors:  Iris R Bell; Barbara Sarter; Mary Koithan; Prasanta Banerji; Pratip Banerji; Shamini Jain; John Ives
Journal:  Glob Adv Health Med       Date:  2014-01

5.  Homeopathic medications as clinical alternatives for symptomatic care of acute otitis media and upper respiratory infections in children.

Authors:  Iris R Bell; Nancy N Boyer
Journal:  Glob Adv Health Med       Date:  2013-01

6.  Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract.

Authors:  Kausik Bishayee; Sourav Sikdar; Anisur Rahman Khuda-Bukhsh
Journal:  J Pharmacopuncture       Date:  2013-12

7.  Embryonic Zebrafish Model - A Well-Established Method for Rapidly Assessing the Toxicity of Homeopathic Drugs: - Toxicity Evaluation of Homeopathic Drugs Using Zebrafish Embryo Model.

Authors:  Himanshu R Gupta; Yogesh Patil; Dipty Singh; Mansee Thakur
Journal:  J Pharmacopuncture       Date:  2016-12

8.  Hormesis and Homeopathy: Toward a New Self-Consciousness.

Authors:  Andrea Dei
Journal:  Dose Response       Date:  2017-11-30       Impact factor: 2.658

9.  New insights into the microscopic interactions associated with the physical mechanism of action of highly diluted biologics.

Authors:  Kristina N Woods
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

Review 10.  Exploring Possible Mechanisms of Hormesis and Homeopathy in the Light of Nanopharmacology and Ultra-High Dilutions.

Authors:  Dana Ullman
Journal:  Dose Response       Date:  2021-06-14       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.